Skip to main content
Premium Trial:

Request an Annual Quote

Celmatix Forms Therapeutics Discovery Division

NEW YORK (GenomeWeb) — Celmatix said today that it has launched a new therapeutics division focused on women's health indications with high unmet need including reproductive disorders and menopause.

Called Celmatix Biosciences, the new division will use Celmatix's Reproductive Atlas program — which is combining biological annotations from peer-reviewed literature with genomic data associated with lifestyle, diet, environment, and reproductive outcomes — to power its drug-discovery activities.

Celmatix Biosciences' most advanced program is in premature ovarian failure and currently in the lead optimization and selection stage, Celmatix said. The unit is also conducting target discovery research in endometriosis, polycystic ovary syndrome, and — with undisclosed funding from the Bill & Melinda Gates Foundation — female contraception.

The launch of Celmatix Biosciences comes about one year after New York City-based Celmatix kicked off expansion efforts following the receipt of $4.5 million in funding from the New York City Regional Economic Development Council and New York State Department of Health approval for its Fertilome multi-gene panel test for reproductive health conditions.

The Scan

Omicron's Emergence

The World Health Organization has called Omicron a SARS-CoV-2 "variant of concern," the Los Angeles Times writes.

Not as Much

Merck's pill to treat COVID-19 reduces the risk of hospitalization and death among COVID-19 patients by less than previously reported, the New York Times says.

Bats That Hang Together

Discover magazine writes that researchers have found a social microbiome among vampire bats.

PLOS Papers on CEWAS, Simian Varicella Virus Transcriptome, Dermatomyositis Markers

In PLOS this week: multi-omic approach to home in on genetic risk variants, transcriptomic analysis of the simian varicella virus, and more.